Table 2.
Clinical and laboratory parameters at baseline and 3 months after treatment*.
| Baseline | 3 months | Percentage change (%) | |
|---|---|---|---|
| Body weight (kg) | |||
| Switch-to-rosuvastatin 40 mg | 79 ± 10 | 79 ± 9 | 0 |
| Add-on-statin ER-NA/laropiprant | 81 ± 10 | 81 ± 10 | 0 |
| SBP (mmHg) | |||
| Switch-to-rosuvastatin 40 mg | 127 ± 14 | 127 ± 12 | 0 |
| Add-on-statin ER-NA/laropiprant | 134 ± 12 | 125 ± 10 | −7††,§ |
| DBP (mmHg) | |||
| Switch-to-rosuvastatin 40 mg | 80 ± 7 | 79 ± 6 | −0.1 |
| Add-on-statin ER-NA/laropiprant | 81 ± 9 | 77 ± 6 | −5†,§ |
| TC, mg/dL (mmol/L) | |||
| Switch-to-rosuvastatin 40 mg | 226 ± 36 (5.8 ± 0.9) | 180 ± 30 (4.7 ± 0.8) | −20†† |
| Add-on-statin ER-NA/laropiprant | 202 ± 42 (5.2 ± 1.1) | 171 ± 37 (4.4 ± 1) | −15†† |
| Triglycerides, mg/dL (mmol/L) | |||
| Switch-to-rosuvastatin 40 mg | 169 (150–189) | 156 (129–183) | −7†† |
| [1.9 (1.7–2.1)] | [1.8 (1.5–2.1)] | ||
| Add-on-statin ER-NA/laropiprant | 164 (141–187) | 123 (97–148) | −25††,§ |
| [1.9 (1.6–2.1)] | [1.4 (1.1–1.7)] | ||
| HDL-C, mg/dL (mmol/L) | |||
| Switch-to-rosuvastatin 40 mg | 55 ± 9 (1.4 ± 0.2) | 54 ± 9 (1.4 ± 0.2) | −0.2 |
| Add-on-statin ER-NA/laropiprant | 47 ± 11 (1.2 ± 0.3) | 53 ± 16 (1.4 ± 0.4) | +13†,§ |
| LDL-C, mg/dL (mmol/L) | |||
| Switch-to-rosuvastatin 40 mg | 142 ± 45 (3.7 ± 1.2) | 98 ± 30 (2.5 ± 0.8) | −30††,‡ |
| Add-on-statin ER-NA/laropiprant | 112 ± 35 (2.9 ± 0.9) | 91 ± 34 (2.4 ± 0.9) | −19†† |
| Non-HDL-C, mg/dL (mmol/L) | |||
| Switch-to-rosuvastatin 40 mg | 175 ± 33 (4.5 ± 0.9) | 127 ± 26 (3.3 ± 0.7) | −40†† |
| Add-on-statin ER-NA/laropiprant | 155 ± 37 (4.0 ± 1) | 118 ± 34 (3.1 ± 0.9) | −24†† |
SBP: systolic blood pressure, DBP: diastolic blood pressure, ER-NA: extended release nicotinic acid, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, non-HDL-C: non-high-density lipoprotein cholesterol.
*Values are expressed as mean ± standard deviation (except for triglycerides which are expressed as median (range)).
† P < .01 versus baseline.
†† P < .001 versus baseline.
§ P < .01 versus and switch-to-rosuvastatin 40 mg group.
‡ P < .01 versus the add-on-statin ER-NA/laropiprant group.